Abstract
Get full access to this article
View all access options for this article.
References
1.US Department of Health and Human Services , Food and Drug Administration, 21 CFR Part 201 [Docket No. 92N-0165], Specific requirements on the content and format of labeling for human prescription drugs: revision of “Pediatric Use” subsection in the labeling . Fed Reg 59(No. 238):64240-50, 13 December 1994 .
2.
Roberts
R
. Assessing safety of investigational drugs . Presentation at the Drug Information Association meeting. Gaithersburg, MD, April 15, 1996 .
3.
Edwards
DJ
Zarowitz
BJ
Slaughter
RL
. Theophylline . In:
Evans
WE
Schentag
JJ
Jusko
WJ
, eds. Applied pharmacokinetics . 3rd ed.
Vancouver, WA : Applied Therapeutics, Inc. , 1992 : 1 –47 .
4.
Burtin
P
Jacqz-Aigrain
E
Girard
P
Lenclen
R
Magny
JF
Betremieux
P
Population pharmacokinetics of midazolam in neonates . Clin Pharmacol Ther
1994 ; 56 : 615 –25 .
5.
Kauffman
RE
Nelson
MV
. Effect of age on ibuprofen pharmacokinetics and antipyretic response . J Pediatr
1992 ; 121 : 969 –73 .
6.
Nahata
MC
. Need for conducting research on medications unlabeled for use in pediatric patients . Ann Pharmacother
1994 ; 28 : 1103 –4 .